Sterile Injectables CDMO Market 2026 expanding toward $10.91 billion by 2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Sterile Injectables CDMO Market During The Forecast Period 2026–2030?

The sterile injectables CDMO market has experienced rapid growth in recent years. Its value is anticipated to rise from $6.65 billion in 2025 to $7.36 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.7%. The expansion observed historically can be attributed to several factors, including limited CDMO infrastructure for sterile injectables, the increasing demand for small molecule injectables, a reliance on in-house formulation development, greater regulatory scrutiny for sterile manufacturing processes, and an overall rise in global pharmaceutical production.

The sterile injectables cdmo market is projected for significant expansion over the coming years. Its valuation is anticipated to reach $10.91 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.3%. This projected growth during the forecast period is driven by factors such as the increasing production of large molecule biologics, a surge in demand for cell and gene therapies, the implementation of advanced aseptic processing methods, a rise in outsourcing to CDMOs, and the escalating need for specialized packaging and cold chain storage. Key trends anticipated in this period encompass a heightened call for contract manufacturing of sterile injectables, the broadening of analytical and testing services to ensure quality, an increase in the production of monoclonal antibodies, peptides, and cell/gene therapies, a greater embrace of lyophilized, emulsion, and reconstitutable injectable forms, and the integration of formulation development with packaging and storage solutions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25912&type=smp

Which Economic Or Industry Drivers Are Impacting The Sterile Injectables CDMO Market?

The rising need for biologics and biosimilars is projected to fuel the expansion of the sterile injectables CDMO market going forward. Biologics are pharmaceuticals derived from living cells or organisms designed to target specific disease elements, while biosimilars are almost exact replicas of authorized biologics, maintaining equivalent quality, safety, and effectiveness. The heightened demand for these treatments stems from the growing prevalence of chronic and intricate health conditions, as these advanced therapies deliver more precise and potent solutions compared to conventional drugs. This increased demand for biologics and biosimilars consequently boosts reliance on sterile injectable CDMO services, given that these therapies are frequently administered through injections and necessitate stringent sterile environments to ensure patient safety, product quality, and regulatory compliance. As an illustration, in February 2025, the Center for Biosimilars, a US-based nonprofit research organization, reported that the US allocated an estimated US $324 billion to biologic medicines in 2023, constituting approximately 45% of the country’s total prescription drug expenditure. Thus, the escalating demand for biologics and biosimilars is a primary catalyst for the growth of the sterile injectables CDMO market.

What Market Segments Are Evaluated Within The Sterile Injectables CDMO Market?

The sterile injectables cdmo market covered in this report is segmented –

1) By Type: Small Molecule, Large Molecule

2) By Service: Formulation Development, Analytical And Testing Services, Manufacturing, Packaging, Storage, Other Services

3) By Route Of Administration: Subcutaneous (SC), Intravenous (IV), Intramuscular (IM), Other Routes Of Administration

4) By Therapeutic Area: Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases, Other Therapeutic Areas

5) By End-User: Pharmaceutical Companies, Biopharmaceutical Companies, Research Institutes, Other End-Users

Subsegments:

1) By Small Molecule: Solutions, Suspensions, Lyophilized Injectables, Emulsions, Reconstitutable Powders

2) By Large Molecule: Monoclonal Antibodies (mAbs), Peptides And Proteins, Vaccines, Cell And Gene Therapies, Insulins And Biosimilars

What Industry Trends Are Redefining The Sterile Injectables CDMO Market?

Leading companies in the Sterile Injectables CDMO market are concentrating on developing innovative solutions, such as modular aseptic filling platforms, to enhance flexibility and efficiency in sterile drug production. Modular aseptic filling platforms are adaptable, isolator-based sterile filling systems built from interchangeable modules that allow CDMOs to quickly switch between vial, syringe, or cartridge formats. This capability helps reduce changeover time, minimize product loss, and efficiently support small- to mid-scale batches for both clinical and commercial sterile injectables. For instance, in February 2025, Recipharm AB, a Sweden-based contract development and manufacturing organization (CDMO), launched a fully operational modular sterile filling system at its Wasserburg, Germany site, specifically designed for aseptic filling of small to mid-scale batches (500–50,000 units). This line minimizes product loss (less than 500 milliliters), supports interchangeable filling modules, and enables efficient processing of high-value biologics within a fully enclosed isolator.

Who Are The Top Market Participants Influencing The Sterile Injectables CDMO Market?

Major companies operating in the sterile injectables cdmo market are Pfizer Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim, Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotechnology Inc.

Read the full sterile injectables cdmo market report here:

https://www.thebusinessresearchcompany.com/report/sterile-injectables-cdmo-global-market-report

What Are The Top-Performing Regions Within The Sterile Injectables CDMO Market?

North America was the largest region in the sterile injectables CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sterile injectables cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Sterile Injectables CDMO Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25912&type=smp

Browse Through More Reports Similar to the Global Sterile Injectables CDMO Market 2026, By The Business Research Company

Generic Oncology Sterile Injectable Market Report 2026

https://www.thebusinessresearchcompany.com/report/generic-oncology-sterile-injectable-global-market-report

Injectable Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/injectable-drug-delivery-devices-global-market-report

Sterile Medical Packaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/sterile-medical-packaging-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795